Spots Global Cancer Trial Database for Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
Official Title: Clinical Study on Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
Study ID: NCT05628545
Conditions
Interventions
Study Description
Brief Summary: Brief Summary: In this study, effects of γδ T cells on Advanced hepatocyte carcinoma The goal of this clinical trial is to learn about effects of allogeneic γδ T therapy in advanced hepatocyte carcinoma patients. The main question it aims to answer is:Will advanced hepatocyte carcinoma patients be benefit from allogeneic γδ T therapy? Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Zhuhai People'S Hospital, Zhuhai, Guangdong, China
Contact Details
Name: Zhi nan Yin, PhD.MD.
Affiliation: Jinan University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
